The researchers propose to develop a Canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions. Because this is an adaptive trial, arms can be dropped if found to be ineffective and new arms can be added.
Interventions will last for 2 months and participants will be followed for an additional 4 months (6 months total). Approximately 800-1000 patients with Long COVID will be recruited across Canada. Results from this trial will accelerate the availability of high-quality, real-time evidence and solutions to enable Canada to improve the clinical care of patients with Long COVID.

开始日期2023-05-31

申办/合作机构

University Health Network

NCT05414240

/ Recruiting临床2期IIT

A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder

This is a research study involving 6 weeks of study medication, Ibudilast or a placebo (an inactive substance) and medical management counseling to reduce or stop drinking. Ibudilast is not approved by the U.S. FDA for clinical use in the United States, but it is has been used for many years in Japan for its anti-inflammatory effects. Its use in the treatment of alcohol dependence is experimental. By reducing inflammation, Ibudilast may help some people reduce or stop drinking. We have obtained an Investigational New Drug Application (IND) approval for this study from the FDA. Ibudilast has been used clinically for 20 years in Asia for treating bronchial asthma and, more recently, for post-stroke dizziness and ocular allergies and has been shown to be safe and well tolerated.

开始日期2023-01-14

申办/合作机构

University of Pennsylvania

NCT04631471

/ Recruiting临床3期IIT

Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy

Degenerative (wear and tear arthritis of the spine) Cervical (concerning the neck) Myelopathy (injury to the spinal cord), DCM, is the most common spinal cord disorder of adulthood. In DCM, arthritis of the spine causes compression of the spinal cord.
The symptoms of DCM are often mistaken for natural consequences of ageing, including numb and clumsy hands, loss of coordination, imbalance, bladder and bowel problems. The weakness can progress to severe paralysis. Every year approximately 4 individuals in 100,000 undergo surgery for DCM; however, many more individuals are thought to suffer from DCM.
The main treatment for DCM is surgery. The aim of surgery is to create space and remove the compression of the spinal cord. This is known to prevent further injury. Unfortunately, the post-operative improvements are often incomplete and many patients remain severely disabled. Improving outcome after surgery represents an important unmet clinical need.
Clinical and preclinical findings indicate that the drug Ibudilast can stimulate neuroprotective and regenerative processes in the spinal cord. Ibudilast is well-tolerated and used to treat asthma and post-stroke dizziness in Japan and is currently being investigated for use in treating other neurological diseases.
This study will investigate whether daily oral administration of Ibudilast for a maximum of 34 weeks can improve hand function, strength, balance, urinary problems and reduce pain.
The study will initially be conducted at three sites in the UK, with more sites added as necessary. Individuals between 18-80 years old, diagnosed with DCM and scheduled for an operation for the first time will be invited to participate in the trial. The study will entail patient questionnaires and clinical assessments before surgery, shortly after surgery and 3, 6, and 12 months after surgery. Moreover, patients will undergo MRI scans pre-operatively and at 6-months postoperatively to determine whether the treatment was successful.

开始日期2021-12-22

申办/合作机构

Cambridge University Hospitals NHS Foundation Trust

100 项与异丁司特相关的临床结果

登录后查看更多信息

100 项与异丁司特相关的转化医学

登录后查看更多信息

100 项与异丁司特相关的专利（医药）

登录后查看更多信息

407

项与异丁司特相关的文献（医药）

2025-05-01·Pain

Glial-modulating agents for the treatment of pain: a systematic review

Review

作者: Xiao, Maggie Z. X. ; Salter, Michael W. ; Gilron, Ian ; Ross-White, Amanda ; Moulin, Dwight E. ; Hutchinson, Mark R. ; Carley, Meg ; Moore, R. Andrew

AbstractPreclinical research supports a critical role for nervous system glia in pain pathophysiology. This systematic review of human trials of potential glia-modulating drugs for the prevention or treatment of pain followed a predefined search strategy and protocol registration. We searched for English language, randomized, double-blind trials comparing putative glia-modulating drugs to placebo or other comparators. The primary outcomes included validated participant-reported measures of pain intensity or relief and, in studies of opioid administration, measures of opioid consumption and/or opioid-related adverse effects. Twenty-six trials (2132 participants) of glial modulators (12 minocycline, 11 pentoxifylline, and 3 ibudilast) were included. Because of clinical heterogeneity related to study drug, participant population, outcome measures, and trial design, no meta-analysis was possible. Only 6 trials reported a positive effect of the treatment (pentoxifylline—4 trials; minocycline—2 trials), whereas 11 trials reported mixed results and 9 trials reported no effect. This review does not provide convincing evidence of efficacy of current pharmacological targets of nervous system glial function for pain treatment or prevention. However, in light of ample preclinical evidence of the importance of neuroimmune signalling and glial functions in pain pathophysiology, continued strategic human research is anticipated to identify (1) drugs with maximal activity as selectively targeted glial modulators, (2) the necessary timing and duration of pharmacological glial modulation needed for pain prevention or treatment for specific injuries or pain conditions, and (3) the best design of future clinical trials of glial-targeted drugs for pain treatment and/or prevention.

2025-05-01·Glia

Ibudilast Protects Retinal Bipolar Cells From Excitotoxic Retinal Damage and Activates the mTOR Pathway

Article

作者: Shalash, Rahaf ; Cebulla, Colleen M. ; Hawthorn, Evan ; Martini, Dena ; Fischer, Andy J. ; Chaurasia, Sameer ; Summitt, Diana ; El‐Hodiri, Heithem M. ; Goswami, Sandeep ; Racine, Julie ; Hamadmad, Sumaya ; Satoskar, Abhay ; Heisler‐Taylor, Tyler ; Sohail, Misha ; Urbanski, Elizabeth G. ; Bernstein, Kayla ; Zatari, Ali

ABSTRACTIbudilast, an inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterase (PDE), has been recently shown to have neuroprotective effects in a variety of neurologic diseases. We utilize a chick excitotoxic retinal damage model to investigate ibudilast's potential to protect retinal neurons. Using single cell RNA‐sequencing (scRNA‐seq), we find that MIF, putative MIF receptors CD74 and CD44, and several PDEs are upregulated in different retinal cells during damage. Intravitreal ibudilast is well tolerated in the eye and causes no evidence of toxicity. Ibudilast effectively protects neurons in the inner nuclear layer from NMDA‐induced cell death, restores retinal layer thickness on spectral domain optical coherence tomography (SD‐OCT), and preserves retinal neuron function, particularly for the ON bipolar cells, as assessed by electroretinography. PDE inhibition seems essential for ibudilast's neuroprotection, as AV1013, the analogue that lacks PDE inhibitor activity, is ineffective. scRNA‐seq analysis reveals upregulation of multiple signaling pathways, including mTOR, in damaged Müller glia (MG) with ibudilast treatment compared to AV1013. Components of mTORC1 and mTORC2 are upregulated in both bipolar cells and MG with ibudilast. The mTOR inhibitor rapamycin blocked accumulation of pS6 but did not reduce TUNEL positive dying cells. Additionally, through ligand‐receptor interaction analysis, crosstalk between bipolar cells and MG may be important for neuroprotection. We have identified several paracrine signaling pathways that are known to contribute to cell survival and neuroprotection and might play essential roles in ibudilast function. These findings highlight ibudilast's potential to protect inner retinal neurons during damage and show promise for future clinical translation.

2025-04-01·Addiction Biology

Ibudilast‐Mediated Suppression of Neuronal TLR4 in the Prefrontal Cortex Mitigates Methamphetamine‐Induced Neuroinflammation and Addictive Behaviours

Article

作者: Lai, Miaojun ; Wang, Fangmin ; Zhou, Wenhua ; Huang, Xiaolei ; Zhou, Yiying ; Wu, Manqing ; Liu, Huizhen ; Zhuang, Dingding ; Liu, Huifen ; Chen, Shanshan ; Ke, Yuting ; Wang, Yuting

ABSTRACTMethamphetamine (METH) use leads to addiction, neurotoxicity, and neuroinflammation. Ibudilast, a toll‐like receptor 4 (TLR4) inhibitor, has been shown to reduce METH‐induced neuroinflammation and self‐administration, but its specific role in neuronal TLR4 signalling and associated behavioural outcomes remains poorly understood. This study examined Ibudilast's effects on METH reward, drug‐seeking behaviour, and TLR4 signalling in a rat self‐administration model. Ibudilast was found to dose‐dependently reduce METH intake and motivation for the drug, as evidenced by a downward shift in the dose–response curve and a decrease in breakpoint. Additionally, Ibudilast suppressed both cue‐ and METH priming‐induced drug‐seeking behaviours. Western blot analysis revealed elevated TLR4, p‐NF‐κB and IL‐6 in the prefrontal cortex after 14 days of METH self‐administration. These increases were significantly attenuated by Ibudilast treatment. Furthermore, local administration of Ibudilast in the prefrontal cortex led to a reduction in METH intake and motivation, as well as decreased TLR4 expression in this brain region. Immunofluorescence staining was revealed that TLR4 was expressed predominantly in neurons and microglia, with METH‐induced upregulation of neuronal TLR4 being linked to apoptosis. Ibudilast restored normal spatial interactions between neurons and microglia, thereby mitigating neuroinflammation and neuronal damage. Furthermore, local injection of Ibudilast in the prefrontal cortex led to a reduction in METH intake and motivation, as well as decreased expression of TLR4 in the brain region. These findings underscore the critical role of neuronal TLR4 in METH addiction and highlight Ibudilast's therapeutic potential in addressing METH‐related neuroinflammation and behavioural dysregulation.

项与异丁司特相关的新闻（医药）

2024-12-06

·EndPoints

Teva to divest business venture in Japan; Layoffs at Rome Therapeutics

Plus, news about Cyclacel Pharmaceuticals, MediciNova and Revolution Medicines: Teva will divest its Japan business venture to private equity firm: The company said Friday that it agreed to transfer all shares of Teva Takeda and its subsidiary Teva Takeda Yakuhin — its businesses that sell generics in Japan — to JKI, a fund managed by J-Will Partners. According to Teva, the divestment will allow Teva to focus on its innovative medicines business in Japan. — Katherine Lewin Rome Therapeutics’ layoffs: The “dark genome” biotech is prioritizing its pipeline and letting go of 17 employees, according to CEO Rosana Kapeller’s LinkedIn post on Thursday. The company is now focused on autoimmune and neurodegenerative diseases. “As we advance both of these programs toward the clinic, we’ll be deprioritizing unrelated areas of dark genome research,” she wrote. — Kyle LaHucik Cyclacel announces plan for strategic alternatives: The company is reviewing options on an “expedited basis” in order to preserve cash, adding that the board also told management to reduce operating costs. Its stock $CYCC was down about 12% on Friday. — Katherine Lewin MediciNova to present interim analysis for ALS drug: MediciNova CMO Kazuko Matsuda said in a statement there’s a “a positive correlation between the 6-month and 12-month data” for ibudilast in a Phase 2/3 trial that enrolled patients with amyotrophic lateral sclerosis. The data are set to be presented this week at the International Symposium on ALS/MND in Canada, and full trial results are expected in 2026. — Katherine Lewin Revolution Medicines raised a total of $862.5 million in its public offering, far more than the $600 million it initially set out to bring in. — Jaimy Lee

并购临床结果

2024-12-05

·GlobeNewswire-Health Care

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company’s COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada. The highlights of the presentation, titled, “COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results” (Abstract # 302), include: Study Update: As of November 15, 2024, a total of 217 participants have been enrolled and 183 participants were assigned to either MN-166 or placebo group.Pre-defined interim analysis was conducted to evaluate the correlation between the 6-month and 12-month data and assess the 12-month double-blind phase trial design.A subset of patients from the full analysis set who had ALSFRS-R data at 6 months and at least one post-6-month data point. Correlation analysis of the Combined Assessment of Function and Survival (CAFS) scores at 6 and 12 months as well as modified CAFS scores and ALSFRS-R scores were evaluated.Positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70), and ALSFRS-R (0.69). [Note: Values in parentheses are Spearman Rank Correlation coefficients]Positive correlations were also observed for Bulbar score (0.74), Fine motor score (0.71), and Gross motor score (0.67), but not for Respiratory score. [Note: Values in parentheses are Spearman Rank Correlation coefficients]Interim analysis results were reviewed and validated by an external independent Data Safety Monitoring Board (DSMB), which recommended that the trial continue as per the protocol. MediciNova CMO and Director Kazuko Matsuda commented, "The interim analysis showed a positive correlation between the 6-month and 12-month data. We considered a change in the treatment period, decided to continue the trial with the current treatment plan based on the DSMB's recommendation. We believe these results will be valuable in designing studies for rapidly progressing diseases like ALS. As of mid-November 2024, over 200 patients have been enrolled and more than 180 patients assigned, if we continue to actively enroll in the COMBAT-ALS study, we expect to complete patient assignments by June 2025 with trial results expected in 2026. Concurrently, we have been supporting continued treatment for those patients wishing to continue MN-166 treatment after the 6-month open-label phase via the FDA's Expanded Access Program (EAP). Next year, the NIH-funded, large-scale Expanded Access Program trial is set to begin, and we look forward to the opportunity to provide access to MN-166 to more ALS patients.” About MN-166 (ibudilast) MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2023 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT: David H. Crean, Ph.D.Chief Business OfficerMediciNova, Incinfo@medicinova.com

临床2期临床3期临床结果

2024-11-20

·PRNewswire

WideTrial Supports NIH-Funded Expanded Access Program for Investigational ALS Drug

Program to provide investigational drug to ALS patients who would otherwise be ineligible for clinical trials SANTA CLARA, Calif., Nov. 20, 2024 /PRNewswire/ -- WideTrial, an innovator of expanded access program (EAP) solutions, announced its participation in an NIH-funded collaboration to provide pre-approval access to an investigational ALS drug. The program will offer access to ibudilast, an experimental drug being studied for its potential to slow the progression of ALS, to patients who are ineligible for clinical trials. Continue Reading WideTrial is participating in a program to provide pre-approval access to an investigational ALS drug. It will offer access to ibudilast, an experimental drug being studied for its potential to slow the progression of ALS, to patients who are ineligible for clinical trials. The program is funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and will be led by Dr. Bjorn Oskarsson at Mayo Clinic's ALS Center of Excellence in Jacksonville, Florida. The program is funded by a $22 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and will be led by Dr. Bjorn Oskarsson at Mayo Clinic's ALS Center of Excellence in Jacksonville, Florida. It aims to enroll 200 ALS patients across all three Mayo Clinic centers and other participating institutions. WideTrial will support the program by engaging a growing group of ALS specialists, enabling greater diversity of patient location and background in the treatment program. The study aims to measure ibudilast's effect on ALS progression using a blood test that shows whether neurofilament protein levels have changed in patients with ALS. High levels of neurofilament proteins may indicate damage in neurons. "We are pleased to support this important initiative to expand access to investigational ALS treatments," said Jess Rabourn, CEO of WideTrial. "At WideTrial, we believe every patient deserves a chance to explore potential therapies, regardless of their eligibility for traditional research trials. The collaboration is part of our commitment to empowering patients and providers with solutions that democratize access to research-stage medicines." WideTrial's expertise in expanded access programs will help ensure the efficient and compliant implementation of the NIH-funded study. Expanded Access provides a pathway for patients with serious or life-threatening conditions who cannot participate in clinical trials to access investigational drugs. Group-level Expanded Access Programs (EAPs) allow a greater number of patients and their physicians to explore a new investigational treatment under a well-designed protocol and supply chain, working in harmony with the continued clinical development of the treatment. When integrated into the drug development cycle, EAPs offer benefits such as wider patient engagement, increased chances of discovering response-predictive biomarkers, and information that leads to more targeted pivotal trials. About WideTrial WideTrial is an integrated service and technology platform that delivers scalable, group-level Expanded Access programs (EAPs) that are easy to participate in and improve patient access to investigational treatments. The company's mission is to bridge the gap between patients and potentially life-saving therapies by streamlining and simplifying the EAP process. WideTrial's expertise and commitment to patient-centric solutions enable healthcare providers and drug developers to efficiently and compliantly offer expanded access to investigational drugs. To learn more, visit widetrial.com. Media Contact : WideTrail: Francis Greenleaf | [email protected] ZingPR for WideTrail: Tim Cox | [email protected] SOURCE WideTrial Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床研究

100 项与异丁司特相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01385	异丁司特	R03DC04	DB05266

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
哮喘	日本	KYORIN Pharmaceutical Co., Ltd.	1989-01-17
脑出血	日本	KYORIN Pharmaceutical Co., Ltd.	1989-01-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脊髓型颈椎病	临床3期	-	MediciNova, Inc.	2022-03-01
肌萎缩侧索硬化	临床3期	加拿大	MediciNova, Inc.	2020-05-28
肌萎缩侧索硬化	临床3期	美国	MediciNova, Inc.	2020-05-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04057898 (COMBAT-ALS, GlobeNewswire) 人工标引	临床2/3期	肌萎缩侧索硬化	183	MN-166	獵鑰製襯糧餘餘衊鑰醖(築膚簾簾構鹹廠蓋繭廠) = Positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70), and ALSFRS-R (0.69). [Note: Values in parentheses are Spearman Rank Correlation coefficients] Positive correlations were also observed for Bulbar score (0.74), Fine motor score (0.71), and Gross motor score (0.67), but not for Respiratory score. [Note: Values in parentheses are Spearman Rank Correlation coefficients] 遞壓艱糧鬱夢餘艱遞遞 (顧獵壓艱構獵網鑰繭選 )	积极	2024-12-05
				placebo
NCT03594435 (CTgov)	临床2期	酒精使用障碍	102	Ibudilast (Ibudilast)	網醖製糧選齋鹽遞積繭(繭鑰廠衊顧鏇鹽鏇鬱醖) = 積衊夢鏇願選簾壓壓鏇廠齋獵鹽餘壓遞鑰醖範 (顧鬱襯窪範製築範蓋鏇, 鹹糧醖製遞鹹鹹膚築鏇 ~ 廠觸鹹遞鑰遞艱選網鏇) 更多	-	2024-11-27
				Placebo oral capsule (Placebo Oral Capsule)	網醖製糧選齋鹽遞積繭(繭鑰廠衊顧鏇鹽鏇鬱醖) = 構壓範遞衊鬱網夢夢艱廠齋獵鹽餘壓遞鑰醖範 (顧鬱襯窪範製築範蓋鏇, 膚鏇鹽獵糧網糧壓觸鬱 ~ 遞獵蓋窪構齋遞醖窪齋) 更多
NCT02714036 (CTgov)	临床1/2期	肌萎缩侧索硬化	35	ibudilast (Regular)	夢廠齋淵鏇鬱選鹹蓋願(獵夢製鹹衊艱夢壓製艱) = 網餘鬱網窪製憲夢鑰糧夢憲壓蓋襯膚膚壓鹹窪 (顧齋鏇糧壓觸選願簾積, 製鹹壓餘壓襯窪醖鹹築 ~ 鬱淵製襯壓構鏇遞獵選) 更多	-	2024-09-24
				ibudilast (Flexible)	網膚願簾廠壓顧憲醖襯(鹹遞廠膚蓋獵繭網壓網) = 淵蓋鑰鹽獵窪憲蓋鹹願壓繭範鹹觸廠獵醖鑰鑰 (簾餘襯衊製齋願艱鏇窪, 壓鏇構憲壓選壓鑰鏇築 ~ 觸範鏇築淵齋餘壓簾鬱) 更多
NCT03782415 (ASCO2024) 人工标引	临床1/2期	胶质母细胞瘤 CD74 expression	62	Ibudilast temozolomide	(壓淵鏇蓋獵範襯選築鹽) = Ibudilast 50 mg BID 醖鬱餘顧憲獵糧襯鹽蓋 (淵繭築蓋簾窪鑰窪願膚 )	积极	2024-05-24
				Ibudilast temozolomide
NCT03782415 (GlobeNewswire) 人工标引	临床2期	胶质母细胞瘤一线	62	MN-166+temozolomide	-	积极	2023-11-19
				MN-166+temozolomide (newly diagnosed GBM)	(窪鹹廠顧窪簾獵廠窪簾) = 醖襯顧窪觸獵築鏇繭製範膚艱構網顧積衊壓鏇 (觸襯淵範鏇構蓋鬱膚積 )
MN166-GBM-1201 (SNO2023)	临床1/2期	胶质母细胞瘤 CD3+ \| CD74 \| CD11b ... 更多	62	MN-166 and TMZ combination therapy	遞網願膚鹹餘觸製鹽積(夢膚憲願顧襯醖醖衊製) = 簾艱衊鹹壓鹹選鑰築選廠鑰鹹壓積醖膚糧蓋選 (構鑰範膚積製網衊簾鏇 )	积极	2023-11-10
ACTRIMS2023	N/A	-	-	Ibudilast	(鹽齋憲衊醖窪醖範鏇獵) = 顧鹽築醖壓鹽衊簾選顧選願鏇鏇繭鏇構憲選鹹 (鹹鬱遞簾簾獵遞壓選廠 ) 更多	-	2023-05-30
				Placebo	(鹽齋憲衊醖窪醖範鏇獵) = 願獵範鏇廠蓋憲積顧鑰選願鏇鏇繭鏇構憲選鹹 (鹹鬱遞簾簾獵遞壓選廠 ) 更多
NCT04429555 (Corporate Publications) 人工标引	临床2期	新型冠状病毒感染 \| 成人呼吸窘迫综合征	34	MN-166	(觸積襯窪鏇鹹鬱獵襯範) = 鬱蓋簾鹹窪壓鹽獵艱淵艱衊齋衊鏇獵顧選壓遞 (願膚繭積築廠鏇膚艱築 ) 更多	积极	2022-06-08
				Placebo	(觸積襯窪鏇鹹鬱獵襯範) = 製鏇鹽願糧襯鹽糧艱積艱衊齋衊鏇獵顧選壓遞 (願膚繭積築廠鏇膚艱築 ) 更多
NCT02238626 (IBU-ALS-1201, CTgov)	临床2期	肌萎缩侧索硬化	70	MN-166+riluzole (MN-166)	鏇鏇鹽範憲膚繭願範艱(壓餘網壓壓顧淵構簾獵) = 顧積廠餘繭範範衊製膚選襯願廠窪窪觸鑰夢憲 (蓋築製構餘遞壓襯蓋膚, 壓築餘選築築蓋淵範蓋 ~ 艱積淵網構鹹獵鬱鹽憲) 更多	-	2021-11-05
				Placebo (for MN-166)+riluzole (Placebo (for MN-166))	遞願顧蓋襯獵膚築願齋(窪鹹齋遞鬱廠餘積範顧) = 網憲繭鹹願簾夢遞顧鹽鹹簾憲築夢餘廠膚憲構 (願築憲顧鹹襯膚築顧淵, 蓋蓋網築憲醖糧觸鑰鹽 ~ 鹽鬱範鏇鑰鬱膚構齋顧)
NCT01982942 (SPRINT-MS, ECTRIMS2021)	临床2期	慢性进行性多发性硬化	-	Ibudilast	壓網願衊糧窪鏇構窪願(廠簾壓鬱鏇構遞鑰壓鑰) = 觸鬱齋醖遞襯窪鹽醖簾夢鏇壓鑰憲窪製衊鑰膚 (簾獵壓鑰糧構築膚觸獵, 0.20)	-	2021-10-12
				Placebo	壓網願衊糧窪鏇構窪願(廠簾壓鬱鏇構遞鑰壓鑰) = 憲鑰鬱窪築鏇鬱憲壓憲夢鏇壓鑰憲窪製衊鑰膚 (簾獵壓鑰糧構築膚觸獵, 0.20)